Why Eli Lilly is Winning the Weight Loss War

Key Concepts

• GLP-1 (Glucagon-like peptide-1): A class of drugs initially for diabetes, now highly effective for weight loss.
• WGOI (Wegovy): Novo Nordisk’s GLP-1 drug for weight loss.
• Zepbound: Eli Lilly’s GLP-1 drug for weight loss.
• Ompeic & Mount Jarro: Blockbuster diabetes drugs from Eli Lilly.
• Kagrima: Novo Nordisk’s newer drug intended to surpass Wegovy in weight loss efficacy.
• Head-to-Head Trial: A clinical trial directly comparing two treatments to determine which is more effective.

The Shift in the GLP-1 Market: Eli Lilly’s Ascendancy

For approximately a century, Eli Lilly and Novo Nordisk have been primary competitors in the diabetes treatment market, both initially dominating insulin production without a definitive winner emerging. The expectation with the burgeoning GLP-1 market was that both companies, already successful with drugs like Eli Lilly’s Ompeic and Mount Jarro, would benefit from the increased demand. This initial assumption proved partially correct, but ultimately led to a significant market shift.

Initial Novo Nordisk Lead & Eli Lilly’s Response

Novo Nordisk initially gained a first-mover advantage with the 2021 approval of WGOI (Wegovy) for weight loss, enjoying a period of market exclusivity. However, this lead was short-lived. Eli Lilly entered the market with Zepbound, a GLP-1 drug that demonstrated superior weight loss results in clinical trials compared to WGOI. This difference in efficacy proved crucial.

Market Share & Stock Performance Divergence

As the GLP-1 market expanded, market share gradually transitioned from Novo Nordisk to Eli Lilly. By early 2025, Eli Lilly had surpassed Novo Nordisk in market share. This shift is directly reflected in the stock market performance of both companies. Until mid-2024, their stock prices moved in tandem, reflecting the anticipated growth of the GLP-1 sector. Following this point, Eli Lilly’s stock continued to rise, while Novo Nordisk’s experienced a significant decline, indicating investor confidence shifting decisively towards Eli Lilly. This demonstrates a move away from betting on GLP-1 as a class and towards betting on Eli Lilly specifically.

Kagrima’s Failure to Reclaim Market Position

Novo Nordisk attempted to regain lost ground with Kagrima, a new drug designed to deliver greater weight loss than WGOI. However, a direct, head-to-head clinical trial comparing Kagrima to Eli Lilly’s Zepbound revealed that Zepbound remained the more effective treatment. This outcome further solidified Eli Lilly’s position.

Historical Context & Speed of Market Decision

The video highlights the contrast in the duration of competitive battles within the pharmaceutical industry. The century-long “insulin war” between Eli Lilly and Novo Nordisk stands in stark contrast to the rapid resolution of the GLP-1 war, potentially decided within just three years. This suggests a faster pace of innovation and market response in the current pharmaceutical landscape.

Key Takeaway

The competition in the GLP-1 weight loss market has resulted in a clear victor: Eli Lilly. Driven by the superior efficacy of Zepbound, demonstrated in clinical trials and confirmed by market share and stock performance, Eli Lilly has overtaken Novo Nordisk, despite Novo Nordisk’s initial lead with WGOI and subsequent attempt with Kagrima.